HC Wainwright & Co. analyst Andrew Fein reiterates Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $50 price target.
HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $50 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $50 price target.
Related Posts
Keybanc Maintains Overweight on Take-Two Interactive, Lowers Price Target to $124
Keybanc analyst Tyler Parker maintains Take-Two Interactive (NASDAQ:TTWO) with a Overweight and lowers the price target from $125 to $124.
Insight Will Be Among The First To Adopt Windows-Based AI PCs With Dedicated Neural Processing Units Powered By Qualcomm Snapdragon X Elite Processor
Insight will test enterprise generative AI applications of next-gen devices, including Qualcomm's Snapdragon X Elite NPU, the first to power a new era of Windows 11 with Copilot and AI built inInsight Enterprises
Cheaper Tesla Coming? EV Maker Reportedly Plans To Make 4M ‘Smaller’ Model Ys Per Year
Electric Vehicle giant Tesla Inc (NASDAQ:TSLA) is said to be planning to make millions of units of a…